GLP‑1 use: a signaling warning

Your gut already has a built-in text message system for eating. Cells in the intestine release glucagon-like peptide 1 after a meal, and that signal travels through nerves and the brain to slow eating and increase fullness. (jci.org) The new weight-loss drugs work by amplifying that same message. Semaglutide, sold as Wegovy and Ozempic, is a glucagon-like peptide 1 receptor agonist, and tirzepatide, sold as Zepbound and Mounjaro, activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors. (accessdata.fda.gov 1) (accessdata.fda.gov 2) One reason these drugs cut food intake is mechanical, not just mental. Zepbound’s label says tirzepatide delays stomach emptying, and the effect is greatest after the first 5 milligram dose before diminishing with later doses. (pi.lilly.com) Another reason is brain signaling. A 2026 review in the Journal of Clinical Investigation says the weight-loss effect of glucagon-like peptide 1 receptor agonists depends on lowering energy intake through the central nervous system, which is the network that processes hunger, reward, and nausea. (jci.org) That is why some clinicians are now warning about a practical problem after months on treatment. If a drug keeps the “I’m full” message turned up for long enough, a patient may need deliberate meal planning to tell the difference between true hunger, mild appetite, and medication-suppressed cues. (x.com) (academic.oup.com) There is an important line between mechanism and proof. Researchers have strong evidence that these drugs change gut-brain appetite signaling, but there is not yet a standard clinical diagnosis called “blunted hunger recognition from chronic glucagon-like peptide 1 therapy” in drug labels or treatment guidelines. (accessdata.fda.gov) (jci.org) What doctors do have is a clue from what happens when treatment stops. In the STEP 1 extension, people who had taken semaglutide regained 11.6 percentage points of lost weight within a year after withdrawal, which suggests the drug was doing ongoing work rather than permanently resetting appetite biology. (ichgcp.net) The official labels also quietly point to the same system being powerfully altered. Wegovy, Ozempic, and Zepbound all carry warnings about delayed stomach emptying and rare reports of pulmonary aspiration during anesthesia, which is what can happen when food remains in the stomach longer than expected. (accessdata.fda.gov 1) (accessdata.fda.gov 2) (accessdata.fda.gov 3) The practical takeaway is less dramatic than the online debate. These drugs are approved to be used with a reduced-calorie diet and increased physical activity, and that wording matters because medication-driven appetite changes still need structure, protein targets, and regular meals to prevent under-eating one day and rebound eating the next. (accessdata.fda.gov 1) (accessdata.fda.gov 2) So the warning circulating this week is best read as a clinical caution, not a settled finding. The science says glucagon-like peptide 1 drugs reshape the gut-brain conversation around eating, and the open question is how well that conversation returns to normal after long-term use in real patients outside trials. (x.com) (academic.oup.com)